The content on this site is intended for healthcare professionals only
Dr Henk Lokhorst presented the results from a phase I/II study in advanced Multiple Myeloma at the 18th EHA meeting.
Multiple myeloma is the second most common haematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Relapsed refractory multiple myeloma
Multiple myeloma (A cancer arising from plasma cells)
